Panel of genetic markers for predicting the risk of developing dry eye disease of various etiologies
https://doi.org/10.21518/2079-701X-2021-12-366-373
Abstract
Introduction. World statistics indicate an increase in patients, including young people, suffering from dry eye disease (DED). Along with exogenous factors, the development of DED depends on a genetic predisposition. Changes in the expression of genes PTPN22, TRIM21, directly or indirectly affecting the T-cell link of immunity, leads to overproduction of cytokines and, as a consequence, damage to the ocular surface.
This study aimed to design a diagnostic panel of genetic markers to determine the risk for DED of various etiologies development.
Materials and methods. The study included 154 patients with autoimmune diseases with and without established DED. With a diagnosis of rheumatoid arthritis (RA) n = 79 and primary Sjogren’s syndrome (PSS) n = 75. The control group consisted of 100 people without ophthalmic diseases, 31 patients with exogenous DED. In this study, we use melting curve analysis to confirm the results of the association analysis for polymorphic markers in genes.
Results. The prognostic value of the predisposing genotypes of the TRIM21 gene of the markers rs915956 and rs7947461 with the risk of DED in the presence of RA (p ≤ 0.001), the marker rs4144331 at the tendency level (p ≤ 0.1) was determined. The risk of developing DES against the background of PSS is associated with the presence of the predisposing genotypes of the TRIM21 genes, the rs4144331 marker, and the PTPN22 rs33996649 marker (p ≤ 0.001). The association of polymorphic markers of the TRIM21 rs7947461 gene and the PTPN22 gene of the rs33996649 marker (p ≤ 0.01) with the risk of developing exogenous DED was established.
Conclusions. The predisposing genotypes were identified and the associations of polymorphic markers of the TRIM21, PTPN22 genes were established. A diagnostic panel of genetic markers has been created to predict DED of various etiologies.
About the Authors
T. N. Safonova
Research Institute of Eye Diseases
Russian Federation
Russian Federation
Cand. Sci. (Med.), Leading Researcher of the Department of Pathology of the Lacrimal System,
11 A, B, Rossolimo St., Moscow, 119021
G. V. Zaitseva
Research Institute of Eye Diseases
Russian Federation
Russian Federation
Junior Researcher, Department of Lacrimal System Pathology,
11 A, B, Rossolimo St., Moscow, 119021
A. M. Burdennyy
Institute of General Pathology and Pathophysiology
Russian Federation
Russian Federation
Cand. Sci. (Biol.), Leading Researcher, Laboratory of Pathogenomics and Transcriptomics,
8, Baltiyskaya St., Moscow, 125315
V. I. Loginov
Institute of General Pathology and Pathophysiology
Russian Federation
Russian Federation
Cand. Sci. (Biol.), Leading Researcher, Laboratory of Pathogenomics and Transcriptomics,
8, Baltiyskaya St., Moscow, 125315
References
1. Craig J.P., Nelson J.D., Azar D.T., Belmonte C., Bron A.J., Chauhan S.K. et al. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017;15(4):802–812. https://doi.org/10.1016/j.jtos.2017.08.003.
2. Şimşek C., Doğru M., Kojima T., Tsubota K. Current Management and Treatment of Dry Eye Disease. Turk J Ophthalmol. 2018;48(6):309–313. https://doi.org/10.4274/tjo.69320.
3. Uchino M. What We Know About the Epidemiology of Dry Eye Disease in Japan. Invest Ophthalmol Vis Sci. 2018; 59(14):1–6. https://doi.org/10.1167/iovs.17-23491.
4. Aggarwal S., Galor A. What’s new in dry eye disease diagnosis? Current advances and challenges. F100Res. 2018;7:F1000 Faculty Rev-1952. https://doi.org/10.12688/f1000research.16468.1
5. Polunin G.S., Kurenkov V.V., Safonova T.N., Polunina E.G. New clinical classification of dry eye syndrome. Refraktsionnaya khirurgiya i oftalmologiya = Refractive Surgery and Ophthalmology. 2003;3(3):53–56. (In Russ.) Available at: https://aktipol.com/usr/files/article_dry_eye.pdf.
6. Safonova T.N., Vasil’ev V.I., Likhvantseva V.G. Sjogren syndrome. Moscow: Lomonosov Moscow State University; 2013. 600 р. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=28059569.
7. Khaitov P.M., Yarilin A.A., Pinegin B.V. Immunology: atlas. Moscow: GEOTARMedia; 2011. 624 р. (In Russ.) Available at: http://webirbis.kgmu.kz/irbis64r_11/books/Р.М.Хаитов_Иммунология.pdf.
8. Bolstad A.I., Jonsson R. Gene Therapy Gene therapeutics in Sjögren’s syndrome. Expert Opin Biol Ther. 2005;5(6):763–772. https://doi.org/10.1517/14712598.5.6.763.
9. El-Asrar A.M., Struyf S., Al-Kharashi S.A., Missotten L., Van Damme J., Geboes K. Expression of T lymphocyte chemoattractants and activation markers in vernal keratoconjunctivitis. Br J Ophthalmol. 2002;86 (10):1175–1180. https://doi.org/10.1136/bjo.86.10.1175.
10. Albertsmeyer A.C., Kakkassery V., Spurr-Michaud S., Beeks O., Gipson I.K. Effect of pro-inflammatory mediators on membrane-associated mucins expressed by human ocular surface epithelial cells. Exp Eye Res. 2010;90(3):444–451. https://doi.org/10.1016/j.exer.2009.12.009.
11. Tamhane M., Cabrera-Ghayouri S., Abelian G., Viswanath V. Review of Biomarkers in Ocular Matrices: Challenges and Opportunities. Pharm Res. 2019;36(3):40. https://doi.org/10.1007/s11095-019-2569-8.
12. McDermott A.M., Perez V., Huang A.J., Pflugfelder S.C., Stern M.E., Baudouin C. et. al. Pathways of corneal and ocular surface inflammation: a perspective from the cullensymposium. Ocul Surf. 2005;3(4 Suppl.): S131–138. https://doi.org/10.1016/s1542-0124(12)70238-0.
13. Marshall L.L., Stevens G.A. Management of Primary Sjögren’s Syndro. Consult Pharm. 2018;33(12):691–701. https://doi.org/10.4140/TCP.n.2018.691.
14. Kuklinski E., Asbell P.A. Sjogren’s syndrome from the perspective of ophthalmology.ClinImmunol. 2017;182:55–61. https://doi.org/10.1016/j.clim.2017.04.017.
15. Zlatanović G., Veselinović D., Cekić S., Zivković M., Dorđević-Jocić J., Zlatanović M. Ocular manifestation of rheumatoid arthritis-different forms and frequency. Bosn J Basic Med Sci. 2010;10(4):323–327. https://doi.org/10.17305/bjbms.2010.2680.
16. Kang M.H., Kim M.K., Lee H.J., Lee H.I., Wee W.R., Lee J.H. Interleukin-17 in various ocular surface inflammatory diseases. J Korean Med Science. 2011;26(7):938–944. https://doi.org/10.3346/jkms.2011.26.7.938.
17. Daguano C., Bochinia C., Gehllen M. Anterior uveitis in the absence of scleritis in a patient with rheumatoid arthritis: case report. Arq Bras Oftalmol.2011;74(2):132–133. Available at: https://pubmed.ncbi.nlm.nih.gov/21779672/.
18. Kemeny-Beke A., Szodoray P. Ocular manifestations of rheumatic diseases. Int Ophthalmol. 2020;40(2):503–510. https://doi.org/10.1007/s10792-019-01183-9.
19. Raychaudhuri S., Sandor C., Stahl E.A., Freudenberg J., Lee H.S., Jia X. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012;44(3):291–296. https://doi.org/10.1038/ng.1076.
20. Tong X., Li Z., Wu Y., Fu X., Zhang Y., Fan H. COMT 158G/A and CYP1B1 432C/G polymorphisms increase the risk of endometriosis and adenomyosis: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;179:17–21. https://doi.org/10.1016/j.ejogrb.2014.04.039.
21. Safonova T.N., Zaitseva G.V. Molecular genetic examination for dry eye syndrome prognosis. Vestnik Oftalmologii = The Russian Annals of Ophthalmology. 2018;134(3):108–115. https://doi.org/10.17116/oftalma20181343108
22. Zaitseva G.V., Loginov V.I., Burdenniy A.M., Lukina S.S. Association of polymorphisms of the TRIM21 gene with the severity of dry keratoconjunctivitis in rheumatoid arthritis and Sjogren’s disease. Vestnik Oftalmologii = The Russian Annals of Ophthalmology. 2019;135(5):192–198. (In Russ.) https://doi.org/10.17116/oftalma2019135052192.
23. Al-Majdoub M., Koy C., Lorenz P., Thiesen H.J., Glocker M.O. Mass spectrometric and peptide chip characterization of an assembled epitope: analysis of a polyclonal antibody model serum directed against the Sjögren/ systemic lupus erythematosus autoantigen TRIM21. J Mass Spectrom. 2013;48(6):651–659. https://doi.org/10.1002/jmr.3208.
24. Begovich A.B., Carlton V.E., Honigberg L.A., Schrodi S.J., Chokkalingam A.P., Alexander H.C. et al. A missense singlenucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004;75(2):330–337. https://doi.org/10.1086/422827.
25. Bottini N., Peterson E.J. Tyrosine Phosphatase PTPN22: multifunctional regulator of immune signaling, development and disease. Annu Rev Immunol. 2013;32:83–119. https://doi.org/10.1146/annurevimmunol-032713-120249.
26. Huang J.J., Qiu Y.R., Li H.X., Sun D.H., Yang J., Yang C.L. A PTPN22 promoter polymorphism 21123G>C is associated with RA pathogenesis in Chinese. Rheumatol Int. 2012;32(3):767–771. https://doi.org/10.1007/s00296-010-1705-x.
Review
For citations:
Safonova TN, Zaitseva GV, Burdennyy AM, Loginov VI. Panel of genetic markers for predicting the risk of developing dry eye disease of various etiologies. Meditsinskiy sovet = Medical Council. 2021;(12):366-373. (In Russ.) https://doi.org/10.21518/2079-701X-2021-12-366-373
Views:
569
Email this article 